In BCR-ABL1-negative myeloproliferative neoplasms (MPNs) thrombo-hemorrhagic complications represent the most common cause of morbidity and mortality. In particular, the reported overall incidence of major thrombotic events ranges from 1.75 to 5.5% events patient-years according to the specific MPN subtype [1]. Arterial thrombotic events, including ischemic stroke, acute coronary syndrome and peripheral arterial thrombosis, account for the majority of these complications (60–70%); accidents in the venous compartment, i.e.
